| | Today's Big News Sep 14, 2022 Sen. Lindsey Graham (R-SC) has proposed a federal 15-week abortion ban, tossing additional fuel on one of the most heated and consequential topics impacting this November's midterm elections. A team of biotech big wigs have launched a new mRNA venture, Capstan Therapeutics, infused with $165 million in early cash funded in part by five Big Pharmas. Almost two years after first being authorized, a South Africa vaccine company has produced the first batch of Pfizer's COVID shot. - Max Bayer | Lumanity’s research scientists and data luminaries can identify fit-for-purpose RWD and design studies to generate the strongest evidence to meet stakeholder needs. Learn more. 
|
| By Robert King Sen. Lindsey Graham introduced legislation Tuesday to install a nationwide ban on abortion after 15 weeks as physicians remain confused over how to abide by conflicting state laws. |
|
|
By Nick Paul Taylor The VC wings of Pfizer, Bayer, Novartis, Eli Lilly and Bristol Myers Squibb have come together to support the birth of a new biotech: Capstan Therapeutics. Armed with $165 million from the companies and VCs, the startup will advance a CAR-T therapy produced inside patients toward clinical development. By Zoey Becker More than a year after partnering with Pfizer to boost COVID-19 vaccine supply in Africa, South Africa's Biovac has produced its first batch of shots, Bloomberg reports. The development follows setbacks for the partnership between Johnson & Johnson and Aspen Pharmacare. By Heather Landi Big tech and retail giants like Amazon and Walmart joined hundreds of provider groups, hospitals and virtual care companies pressing Congress to take action on telehealth legislation this fall. By Nick Paul Taylor Pfizer has begun a phase 3 clinical trial of its mRNA-based influenza vaccine, keeping it tucked in behind Moderna in the race to upend the seasonal flu market using the technology that defined the response to COVID-19. By Kevin Dunleavy Even at a hefty price tag of $2.5 million per treatment, oncoming gene therapies can be the most cost-effective way for patients with hemophilia types A and B to deal with their condition. That’s the conclusion of the Institute for Clinical and Economic Review (ICER) in a draft evidence report released on Tuesday. By Andrea Park Following its blockbuster buy of medtech manufacturer Hillrom late last year, Baxter may now be preparing to trim some of the fat from its newly expanded product portfolio. By Fraiser Kansteiner The European Court of Auditors is struggling to make headway on its probe into the EU's biggest vaccine contract: a 1.8M-dose deal with Pfizer. By James Waldron Larimar Therapeutics held its breath for over a year, but the FDA has finally given the biotech a green light to continue trials of its lead, and only, asset this year. The therapy, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of Friedreich’s ataxia patients. By Andrea Park The National Institutes of Health has launched a new initiative to build a set of analytics tools and best practices that’ll help researchers get their data ready for AI-powered analysis. By Dave Muoio The impending closure of a major safety net hospital is reportedly prompting a massive scale-up to ensure Atlanta's publicly run health system can handle an influx of new patients. By Gabrielle Masson Altimmune’s phase 1b study evaluating its obesity and non-alcoholic steatohepatitis (NASH) treatment has hit its main target, along with a secondary goal. It makes for some welcome topline data in a notoriously tricky indication. By Conor Hale The Tasso+ lancet can be placed by the user themselves on their upper arm to fill up a small tube of blood drawn from the capillaries. Fierce podcasts Don't miss an episode | This week on "Podnosis," we talk about how the emotional toll from gun violence impacts care in hospitals. We also chat about how investors are approaching the current market. |
|
|---|
|
| Wednesday, September 28, 2022 | 2pm ET / 11am PT Explore the top line items every SMB marketer should focus on when commercializing new-to-market products, including shifts in the way that HCPs interact with pharma companies post-pandemic, and more. Register now. 
|
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn AI eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent | | |
|
